ArticleFrontiers in pediatrics2026
Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Children with IgA vasculitis (IgAV) may develop nephritis after initially presenting without kidney involvement. We evaluated whether a cytokine augmentation score (CAS) was associated with improved six-month incident nephritis risk stratification beyond clinical variables and routine inflammatory markers. Methods: This single-center cohort screened children younger than 18 years with IgAV from January 2023 to June 2024 and used standardized six-month renal outcome ascertainment. Children meeting accepted IgAV classification criteria, with no nephritis during the baseline decision window, complete baseline biomarker data, and six-month renal outcome ascertainment formed the cohort. A routine inflammatory index score (RIIS) summarized Results: Among 447 screened children, 337 were analyzed; 91 (27.0%) developed incident nephritis. CAS was independently associated with nephritis after adjustment for age, sex, symptom-to-blood-draw interval, gastrointestinal involvement, systolic blood-pressure percentile, subthreshold urinary warning signs, and RIIS (adjusted odds ratio per standard deviation (SD), 2.97; 95% confidence interval (CI), 2.01-4.39; Conclusions: In this single-center derivation cohort, CAS improved internally evaluated discrimination, Brier score, and risk separation beyond clinical variables and RIIS. The model remains investigational pending external validation, assay standardization, and implementation testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.